Fig. 3
From: SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1
Downregulation of SIRT1 attenuates tumorigenicity of NSCLC in vivo. (A) Representative image of the tumors harvested from the lv-NC and lv-SIRT1 group (n = 6). (B) Tumor weight was compared between two groups. The tumor volume growth curves of each group were determined. (C) HE staining was used to detect the pathological changes in tumors. Amplification: 400 × , scale bar: 20 μm. (D) IHC images of Ki‐67 in each group. Amplification: 400 × , scale bar: 20 μm. (E) IHC staining of SIRT1 expression in tumor tissues of lv-NC and lv-SIRT1 groups. Amplification: 400 × , scale bar: 20 μm. (F) IHC staining of FOXO1expression in tumor tissues of lv-NC and lv-SIRT1 groups. Amplification: 400 × , scale bar: 20 μm. **p < 0.01 vs. lv-NC.
